Earnings History Data for argenx SE (ARGX) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

argenx SE

argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
25-07-2024	PM		ARGX	argenx SE	27,990	N/A	-0.90	-1.69	argenx SE beats top-line and bottom-line estimates; updates FY24 outlook [7/25/2024 1:08 AM]	486.01	21.65 (4.66%)	489.66	25.30 (5.45%)	327.73 - 534.41	791,868	410,000	14,012
argenx SE beats top-line and bottom-line estimates; updates FY24 outlook [7/25/2024 1:08 AM] Argenx SE 1H Earnings Preview [7/24/2024 1:35 PM] Oppenheimer upgrades argenx to outperform, cites Vyvgart Hytrulo [7/24/2024 10:45 AM]
09-05-2024	PM		ARGX	argenx SE	23,610	-1.04	-0.71	-0.52	argenx misses top-line and bottom-line estimates; updates FY24 outlook [5/9/2024 1:19 AM]	384.11	-1.97 (-0.51%)	374.23	-11.85 (-3.07%)	327.73 - 550.76	520,568	210,000	15,453
argenx misses top-line and bottom-line estimates; updates FY24 outlook [5/9/2024 1:19 AM] Argenx SE Q1 2024 Earnings Preview [5/8/2024 11:19 AM]
29-02-2024	PM		ARGX	argenx SE	22,730	-1.68	-1.23	-0.70	Argenx SE GAAP EPS of -$1.68 misses by $0.30, revenue of $374M beats by $10.28M [2/29/2024 1:40 AM]	381.13	-16.57 (-4.17%)	390.00	-7.70 (-1.94%)	327.73 - 550.76	774,991	250,000	7,650
Argenx SE GAAP EPS of -$1.68 misses by $0.30, revenue of $374M beats by $10.28M [2/29/2024 1:40 AM] Argenx SE Q4 2023 Earnings Preview [2/28/2024 10:52 AM]
31-10-2023	PM		ARGX	argenx SE	26,060	-1.25	-1.48	-4.26	Argenx SE GAAP EPS of -$1.25 beats by $0.18, total operating income of $339.84M beats by $38.12M [10/31/2023 2:16 AM]	470.09	5.94 (1.28%)	478.33	14.18 (3.06%)	333.07 - 550.76	376,310	230,000	2,958
Argenx SE GAAP EPS of -$1.25 beats by $0.18, total operating income of $339.84M beats by $38.12M [10/31/2023 2:16 AM] Argenx SE Q3 2023 Earnings Preview [10/30/2023 3:05 PM]
27-07-2023	PM		ARGX	argenx SE	28,890	-1.69	-1.69	-3.81	Argenx SE GAAP EPS of -$1.69 misses by $0.11, revenue of $281.04M beats by $28.21M [7/27/2023 4:50 AM]	507.69	-13.30 (-2.55%)	0.0	0.0 (0.00%)	333.07 - 550.76	490,112	820,000	0
Argenx SE Q2 2023 Earnings Preview [7/26/2023 3:28 PM] Argenx SE GAAP EPS of -$1.69 misses by $0.11, revenue of $281.04M beats by $28.21M [7/27/2023 4:50 AM]
04-05-2023	PM	1:00 AM ET (May 4)	ARGX	argenx SE	21,870	-0.52	-2.34	-4.36	Argenx SE GAAP EPS of -$0.52 beats by $1.72, revenue of $219.14M beats by $18.6M [5/4/2023 1:06 AM]	396.48	4.19 (1.07%)	389.22	-3.07 (-0.78%)	267.35 - 407.93	331,019	220,000	5,549
Argenx SE GAAP EPS of -$0.52 beats by $1.72, revenue of $219.14M beats by $18.6M [5/4/2023 1:06 AM]
02-03-2023	PM	1:00 AM ET (Mar 2)	ARGX	argenx SE	20,320	-0.70	-3.08	-4.76	Argenx SE GAAP EPS of -$0.70 beats by $2.32, revenue of $174.16M misses by $4.3M [3/2/2023 1:16 AM]	343.81	-25.14 (-6.81%)	356.00	-12.95 (-3.51%)	256.44 - 407.93	988,865	170,000	7,705
Argenx SE GAAP EPS of -$0.70 beats by $2.32, revenue of $174.16M misses by $4.3M [3/2/2023 1:16 AM] Argenx SE FY 2022 Earnings Preview [3/1/2023 1:06 PM] argenx names new COO [3/2/2023 4:40 AM]
27-10-2022	PM	1:00 AM ET (Oct 27)	ARGX	argenx SE	21,450	-4.26	-3.50	-4.40	Argenx SE GAAP EPS of -$4.26 misses by $0.85, total operating income of $146.49M beats by $28.98M [10/27/2022 2:26 AM]	372.76	-10.86 (-2.83%)	401.99	18.37 (4.79%)	249.50 - 403.77	542,143	240,000	14,789
Argenx SE GAAP EPS of -$4.26 misses by $0.85, total operating income of $146.49M beats by $28.98M [10/27/2022 2:26 AM] Argenx inks manufacturing contract for efgartigimod with Fujifilm Diosynth [10/27/2022 5:42 AM]
28-07-2022	PM	1:00 AM ET (Jul 28)	ARGX	argenx SE	19,640	-3.81	-4.77	1.98	Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M [7/28/2022 1:30 AM]	374.89	17.03 (4.76%)	386.50	28.64 (8.00%)	249.50 - 387.89	590,155	230,000	13,965
Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M [7/28/2022 1:30 AM] argenx up 9% premarket on Q2 top and bottom line beats [7/28/2022 6:51 AM] argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022 [Jul-28-22 02:30AM] argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update [Jul-28-22 01:00AM]
05-05-2022	PM		ARGX	argenx SE	15,910	-4.36	-5.08	-0.81	Argenx SE GAAP EPS of -$4.36 beats by $0.50, revenue of $23.41M beats by $8.11M [5/5/2022 1:41 AM]	319.95	27.02 (9.22%)	306.09	13.16 (4.49%)	248.21 - 356.78	904,680	290,000	77,651
Argenx SE Q1 2022 Earnings Preview [5/4/2022 12:28 PM] Argenx SE GAAP EPS of -$4.36 beats by $0.50, revenue of $23.41M beats by $8.11M [5/5/2022 1:41 AM] Argenx says Vyvgart met main goal in late-stage trial for autoimmune blood disorder [5/5/2022 7:16 AM] argenx to Present at BofA Securities 2022 Healthcare Conference [May-04-22 01:00AM] argenx Reports First Quarter 2022 Financial Results and Provides Business Update [May-05-22 01:00AM] argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia [May-05-22 01:00AM] Argenx Stock Climbs as Sales of New Drug Blow Past Expectations [May-05-22 09:11AM] Argenx's Vyvgart Meets Primary Goal In Late-Stage Bleeding Disorder Study [May-05-22 11:00AM]
03-03-2022	PM	1:00 AM ET (Mar 3)	ARGX	argenx SE	14,820	-4.76	-4.88	-4.20	Argenx SE GAAP EPS of -$7.99 beats by $0.26, revenue of $497.28M misses by $7.93M [3/3/2022 1:17 AM]	272.50	-18.86 (-6.47%)	281.00	-10.36 (-3.56%)	248.21 - 356.78	276,736	200,000	21,799
Argenx SE GAAP EPS of -$7.99 beats by $0.26, revenue of $497.28M misses by $7.93M [3/3/2022 1:17 AM] argenx Reports Full Year 2021 Financial Results and Provides Fourth Quarter Business Update [Mar-03-22 01:00AM]
28-10-2021	PM	1:00 AM ET (Oct 28)	ARGX	argenx SE	14,490	-4.40	-4.48	-3.96		280.56	0.98 (0.35%)	281.06	1.48 (0.53%)	245.91 - 382.15	305,074	140,000	5,746
Argenx SE reports 9M results [10/28/2021 2:44 AM] argenx Reports Third Quarter 2021 Financial Results and Provides Business Update [Oct-28-21 01:00AM]
29-07-2021	PM	1:00 AM ET (Jul 29)	ARGX	argenx SE	15,450	1.98	-3.38	-3.15		296.81	-10.69 (-3.48%)	295.60	-11.90 (-3.87%)	212.66 - 382.15	134,530	150,000	4,501
Argenx SE reports 1H results [7/29/2021 1:39 AM] argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update [Jul-29-21 01:00AM]
14-05-2021	PM		ARGX	argenx SE	13,200	-0.81	-3.16	-2.06	Argenx SE reports Q1 results [5/14/2021 2:29 AM]	272.29	11.01 (4.21%)	260.30	-0.98 (-0.38%)	141.26 - 382.15	140,521	140,000	147
Argenx SE reports Q1 results [5/14/2021 2:29 AM] argenx Reports First Quarter 2021 Financial Results and Provides Business Update [May-14-21 01:00AM] argenx SE to Host Earnings Call [May-14-21 06:45AM]
04-03-2021	PM	1:00 AM ET (Mar 4)	ARGX	argenx SE	17,010	-4.20	-2.89	0.00		291.38	-24.86 (-7.86%)	310.30	-5.94 (-1.88%)	103.75 - 382.15	337,944	167,244	1,214

22-10-2020	PM	0:00 AM ET (Oct 22)	ARGX	argenx SE	12,440	-3.96	-2.80	0.00		251.71	-5.09 (-1.98%)	243.57	-13.23 (-5.15%)	103.75 - 284.00	201,742	130,187	3,143